Drugs / allogeneic engineered Gingival Fibroblasts
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06690710 | Aug 2025 → Feb 2027 expected | osteoarthritis, knee | Scarcell Therapeutics S.A.S. | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | allogeneic engineered Gingival Fibroblasts | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06690710 ↗ |
| Known as | aeGF | “the study drug called allogeneic engineered Gingival Fibroblasts (aeGF)” NCT06690710 ↗ |
| Modality | Cell therapy | “an advanced therapy medicinal product (a cell therapy) from human donor cells” NCT06690710 ↗ |